159872-32-9

Basic information

• Product Name: 1-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]undec-10-en-1 -one
• Synonyms: 1-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]undec-10-en-1 -one
• CAS NO: 159872-32-9
• Molecular Formula: C27H44N6O
• Molecular Weight: 468.68
• Mol File: 159872-32-9.mol

Chemical Properties

• Boiling Point: 685.5°Cat760mmHg
• Flash Point: 368.4°C
• Appearance: /
• Density: 1.107g/cm³
• Vapor Pressure: 1.21E-18mmHg at 25°C
• Refractive Index: 1.562
• CAS DataBase Reference: 1-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]undec-10-en-1 -one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]undec-10-en-1 -one(159872-32-9)
• EPA Substance Registry System: 1-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]undec-10-en-1 -one(159872-32-9)

Safety Data

• Hazardous Substances Data: 159872-32-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C27H44N6O/c1-2-3-4-5-6-7-8-9-14-26(34)32-21-19-31(20-22-32)25-23-24(30-15-10-11-16-30)28-27(29-25)33-17-12-13-18-33/h2,23H,1,3-22H2

Upstream product

• 38460-95-6 undec-10-enoyl chloride 
• 111641-17-9 2,4-bis(1-pyrrolidinyl)-6-(1-piperazinyl)-pyrimidine 

Relevant articles and documents

Piperazine and homopiperazine derivatives, pharmaceutical compositions containing them and process for preparing same

This invention relates to novel compounds of the general formula (I) and the pharmaceutically acceptable acid addition salts thereof. In the general formula (I) STR1 wherein Lip, A1, A2, Het and n are defined as in the specification. The compounds of the general formula (I) inhibit the lipid peroxidation and therefore, they are useful for the treatment or prevention of diseases and conditions wherein the inhibition of lipid peroxidation is desirable.

Piperazine and homopiperazine derivatives, pharmaceutical compositions containing them and process for preparing the same

The lipid peroxidation inhibiting piperazine and homopiperazine derivatives of the general formula (I) and the pharmaceutically acceptable acid addition salts thereof, Lip stands for hydrogen; C15 20 alkyl; C10 20 alkanoyl or C10 20 alkenoyl; trityl optionally substituted by halogen; adamantyl; 1- or 2-naphthyloxy or oxo-substituted tetrahydronaphthyloxy; or an amine protective group commonly used e.g. in the peptide chemistry;, A1 and A2 are selected independently from the group consisting of a single bond and C2 3 alkylene optionally substituted by hydroxy or oxo;, n is 1 or 2; and, Het represents, a group of the general formula (a), wherein, R1 is amino or 1-pyrrolidinyl;, or a 4-chloro-3-oxo-2,3-dihydro-5-pyridazinyl group of the formula (b); or a 4-amino-6,7-dimethoxy-2-quinazolinyl group of the formula (c); or a 4,7-diamino-6-phenyl-2-pteridinyl group of the formula (d); or a 2,7-diamino-6-phenyl-4-pteridinyl group of the formula (e); or a 2,4,7-triamino-6-pteridinylcarbonyl group of the formula (f); or a group of the general formula (g); wherein, X means oxygen, sulfur or nitrogen optionally substituted by lower alkyl,with the frist proviso that, when Het stands for a group of the general fromula (a) and both A1 and A2 mean single bonds then Lip may not be hydrogen;, with the second priviso that, when Lip is different from naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A1 means a single bond;, with the third proviso that, when Lip represents naphthyloxy or oxo-substituted tetrahydronaphthyloxy then A1 may not be a single bond, as well as with the fourth proviso that, A1 and A2 cannot simultaneously stand for C2 3 alkylene optionally substituted by hydroxy or oxo.